Last updated on November 2019

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13 in Healthy Infants (V114-031/PNEU-LINK)

Brief description of study

This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13 in healthy infants. This study will include both full-term infants (37 weeks gestational age) and premature infants (<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogenicity Substudy, which will assess immunogenicity and safety following administration of V114 or Prevnar 13.

Clinical Study Identifier: NCT03692871

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.